Applied Genetic Technologies Corp. (NASDAQ:AGTC) CFO Lawrence E. Bullock bought 10,000 shares of the firm’s stock in a transaction that occurred on Monday, September 19th. The stock was purchased at an average cost of $8.75 per share, with a total value of $87,500.00. Following the completion of the purchase, the chief financial officer now directly owns 10,000 shares of the company’s stock, valued at approximately $87,500. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Shares of Applied Genetic Technologies Corp. (NASDAQ:AGTC) opened at 8.89 on Friday. The stock has a 50 day moving average of $12.91 and a 200-day moving average of $14.69. The company’s market cap is $160.49 million. Applied Genetic Technologies Corp. has a 12 month low of $8.50 and a 12 month high of $21.43.

Applied Genetic Technologies Corp. (NASDAQ:AGTC) last released its quarterly earnings results on Monday, September 12th. The company reported $0.15 EPS for the quarter, beating analysts’ consensus estimates of $0.07 by $0.08. The business earned $12.10 million during the quarter. Applied Genetic Technologies Corp. had a negative return on equity of 1.34% and a negative net margin of 2.92%. The company’s quarterly revenue was up 1604.2% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.48) earnings per share. Equities analysts forecast that Applied Genetic Technologies Corp. will post ($0.61) earnings per share for the current year.

Several research firms recently weighed in on AGTC. Cantor Fitzgerald reissued a “buy” rating and issued a $32.00 target price on shares of Applied Genetic Technologies Corp. in a research note on Wednesday, June 22nd. Janney Montgomery Scott cut shares of Applied Genetic Technologies Corp. from a “buy” rating to a “sell” rating and decreased their target price for the company from $23.00 to $11.00 in a research note on Tuesday, September 13th. Wedbush decreased their target price on shares of Applied Genetic Technologies Corp. from $36.00 to $20.00 and set an “outperform” rating for the company in a research note on Tuesday, September 13th. Stifel Nicolaus decreased their target price on shares of Applied Genetic Technologies Corp. from $29.00 to $24.00 and set a “buy” rating for the company in a research note on Tuesday, September 13th. Finally, Wells Fargo & Co. cut shares of Applied Genetic Technologies Corp. from an “outperform” rating to a “market perform” rating in a research note on Tuesday, September 13th. Two equities research analysts have rated the stock with a sell rating, four have issued a hold rating and four have assigned a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus price target of $17.44.

A number of large investors have recently added to or reduced their stakes in AGTC. Numeric Investors LLC raised its stake in Applied Genetic Technologies Corp. by 3.8% in the second quarter. Numeric Investors LLC now owns 720,969 shares of the company’s stock worth $10,187,000 after buying an additional 26,670 shares during the last quarter. Perceptive Advisors LLC raised its stake in Applied Genetic Technologies Corp. by 1.3% in the second quarter. Perceptive Advisors LLC now owns 658,851 shares of the company’s stock worth $9,309,000 after buying an additional 8,260 shares during the last quarter. BlackRock Fund Advisors raised its stake in Applied Genetic Technologies Corp. by 20.1% in the second quarter. BlackRock Fund Advisors now owns 555,987 shares of the company’s stock worth $7,856,000 after buying an additional 93,015 shares during the last quarter. Acadian Asset Management LLC raised its stake in Applied Genetic Technologies Corp. by 68.3% in the second quarter. Acadian Asset Management LLC now owns 498,825 shares of the company’s stock worth $7,047,000 after buying an additional 202,361 shares during the last quarter. Finally, Vanguard Group Inc. raised its stake in Applied Genetic Technologies Corp. by 7.7% in the second quarter. Vanguard Group Inc. now owns 445,962 shares of the company’s stock worth $6,302,000 after buying an additional 31,762 shares during the last quarter. 60.10% of the stock is owned by institutional investors and hedge funds.

About Applied Genetic Technologies Corp.

Applied Genetic Technologies Corp is a United States-based clinical stage biotechnology company. The Company develops gene therapy products for the treatment of inherited and acquired diseases. Its products are used to treat Alpha One Antitrypsin Deficiency (Alpha-1), a respiratory disease caused by deficiencies in the tissue protective protein alpha one antitrypsin; and Lebers congenital amaurosis, an inherited condition causing early blindness.

5 Day Chart for NASDAQ:AGTC

Receive News & Ratings for Applied Genetic Technologies Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Applied Genetic Technologies Corp. and related companies with MarketBeat.com's FREE daily email newsletter.